Archives of Dermatological Research

, Volume 288, Issue 9, pp 543–548 | Cite as

Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA

  • G. P. Rajan
  • B. Seifer
  • O. Prümmer
  • H. I. Joller-Jemelka
  • G. Burg
  • R. Dummer
Original Paper

Abstract

Interferon-α combined with retinoid or PUVA is used for the treatment of cutaneous T-cell lymphoma. Anti-IFN-α antibodies (IFN ab) occur regularly during IFN-α treatment. We investigated the incidence of neutralizing and binding IFN ab and analysed their relationship with clinical and immunological parameters. A group of 17 CTCL patients were treated with IFN alpha-2a three times weekly subeutaneously at a dose of 3 Mill. I.U. combined either with retinoid (acitretin, Neotigason; 0.5 mg/kg body weight) daily or with 5-methoxypsoralen (1.2 mg/kg body-weight) plus UVA radiation three times weekly. Prior to and during treatment we monitored stage, skin involvement by a tumour burden index, serum levels of β2-microglobulin, neopterin, binding and neutralizing IFN ab, Interleukin-6 (IL-6), soluble IL-2 receptors (sIL-2r) and the CD4/CD8 ratio of peripheral blood mononuclear cells. We observed two complete, two partial and six minor responses, four patients with stable disease and three patients with progressive disease. Of the 17 patients, 7 developed binding IFN ab, but only 2 had neutralizing IFN ab which were associated with high titres of binding IFN ab. IFN ab formation was more frequent in patients with normal CD4/CD8 ratios and a high tumour burden index and showed a trend to be more frequent in PUVA-cotreated patients than in retinoid-cotreated patients. Responses were more frequently seen in IFN ab-negative patients. IFN ab developed in patients treated with PUVA or retinoid combined with IFN. Binding as well as neutralizing IFN ab may have an impact on the treatment success in CTCL patients.

Key words

Anti-Interferon antibodies PUVA Retinoid Cutaneous T-cell lymphoma Therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G (1993) Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. J Interferon Res 13: 121–125PubMedGoogle Scholar
  2. 2.
    Bunn PJ, Hoffman SJ, Norris D, Golitz LE, Aeling JL (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 121: 592–602PubMedGoogle Scholar
  3. 3.
    Dianzani F, Antonelli G, Capobianchi MR (1990) The biological basis for clinical use of interferon. J Hepatol 11 [Suppl 1]: S5–10CrossRefGoogle Scholar
  4. 4.
    Dreno B (1993) Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells (Dayt) 11: 269–275CrossRefGoogle Scholar
  5. 5.
    Dummer R, Müller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G (1991) Formation of neutralizing antibodies against natural interferon-β, but not against interferon-γ during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67: 2300–2304PubMedCrossRefGoogle Scholar
  6. 6.
    Dummer R, Nestle F, Wiede J, Schäfer E, Röger J, Erhard H, Hefner H, Burg G (1991) Coincidence of increased soluble interleukin-2 receptors, diminished natural killer cell activity and progressive disease in cutaneous T-cell lymphomas. Eur J Dermatol 1: 135–138Google Scholar
  7. 7.
    Dummer R, Kohl O, Gillisson J, Kägi M, Burg G (1993) Peripheral blood mononuclear cells in non-leukemic cutaneous T-cell lymphoma patients: reduced proliferation and preferential secretion of a T helper 2 like cytokine pattern on stimulation. Arch Dermatol 129: 433–436PubMedCrossRefGoogle Scholar
  8. 8.
    Edelson RL (1980) Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 2: 89–106PubMedCrossRefGoogle Scholar
  9. 9.
    Fuchs D, Weiss G, Reibnegger G, Wachter H (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 29: 307–341PubMedCrossRefGoogle Scholar
  10. 10.
    Gilmour JW, Vestey JP, Norval M (1993) The effect of UV therapy on immune function in patients with psoriasis. Br J Dermatol 129: 28–38PubMedCrossRefGoogle Scholar
  11. 11.
    Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M (1991) Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 24: 247–252PubMedCrossRefGoogle Scholar
  12. 12.
    Kuzel TM, Roenigk HJ, Rosen ST (1991) Mycosis fungoides and the Sezary syndrome: a review of pathogenesis, diagnosis, and therapy, J Clin Oncol 9: 1298–1313PubMedGoogle Scholar
  13. 13.
    Kuzel TM, Roenigk HJ, Samuelson E, Rosen ST (1992) Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J Natl Cancer Inst 84: 119–121PubMedCrossRefGoogle Scholar
  14. 14.
    Laskin JD, Mermelstein FH, Heindel ND, Ron Y (1993) Selective inactivation of lymphocytes after psoralen/ultraviolet light (PUVA) treatment without affecting systemic immune responses. J Leukoc Biol 54: 138–144PubMedGoogle Scholar
  15. 15.
    Leavitt RD, Ratanatharathorn V, Ozer H, Ultmann JE, Portlock C, Myers JW, Kisner D, Norred S, Spiegel RJ, Bonnem EM (1987) Alta-2b interferon in the treatment of Hodgkin’s disease and non-Hodgkin’s lymphoma. Semin Oncol 14: 18–23PubMedGoogle Scholar
  16. 16.
    Mostow EN, Neckel SL, Oberhelman L, Anderson TF, Cooper KD (1993) Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 129: 747–752PubMedCrossRefGoogle Scholar
  17. 17.
    Oberg K (1989) Antibodies in carcinoid syndrome. J Natl Cancer Inst 81: 531–535PubMedCrossRefGoogle Scholar
  18. 18.
    Papa G, Tura S, Mandelli F, Vegna ML, Defazio D, Mazza P, Zinzani PL, Simoni R, DePita O, Ferranti G, et al (1991) Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 48: 48–51CrossRefGoogle Scholar
  19. 19.
    Peakman M Vergani D (1994) Autoimmune disease: etiology, therapy and regeneration. Immunol Today 15: 345–347PubMedCrossRefGoogle Scholar
  20. 20.
    Prummer O (1993) Interferon-alpha antibodies in patients with reanl cell carcinoma treated with recombinant interferon-alpha 2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 71: 1828–1834.PubMedCrossRefGoogle Scholar
  21. 21.
    Quesada JR, Rios A, Swanson D, Tworn P, Gutterman JU (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1522–1528PubMedGoogle Scholar
  22. 22.
    Roenigk H, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PJ, et al (1990) Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95: 198S-205SPubMedCrossRefGoogle Scholar
  23. 23.
    Romagnani S (1992) Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 98: 279–285PubMedCrossRefGoogle Scholar
  24. 24.
    Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL (1988) Resistance to recombinant interferon alpha-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318: 1409–1413PubMedCrossRefGoogle Scholar
  25. 25.
    Wussow P von, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN-alpha antibody titres during interferon therapy (letter). Lancet 2: 635–636Google Scholar
  26. 26.
    Wussow P von, Jakschies D, Freund M, Deicher H (1989) Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy. J Interferon Res 9 [Suppl]: S25–31Google Scholar
  27. 27.
    Zachariae H, Thestrup-Pedersen K (1990) Inteferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95: 206S-208SPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • G. P. Rajan
    • 1
  • B. Seifer
    • 2
  • O. Prümmer
    • 3
  • H. I. Joller-Jemelka
    • 4
  • G. Burg
    • 1
  • R. Dummer
    • 1
  1. 1.Department of DermatologyUniversity of Zürich Medical School, Gloriastr. 31ZürichSwitzerland
  2. 2.Institute of Social and Preventive Medicine, Department of BiostatisticsUniversity of ZürichZürichSwitzerland
  3. 3.Department of Internal Medicine IIIUniversity Hospital of UlmUlmGermany
  4. 4.Department of Clinical ImmunologyUniversity of Zürich Medical SchoolZürichSwitzerland

Personalised recommendations